IDH1 and central nervous system cancer: Vorasidenib is a potent, oral, brain-penetrant dual inhibitor targeting both IDH1 and IDH2 mutants, which is undergoing a phase III INDIGO study (NCT04164901) in patients with residual or recurrent grade II glioma (21).